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Alzheimer’s disease is the most common neurodegenerative disorder and afflicts 
close to 1 million people in the UK (out of a population of 66 million) and 3 
million in the US (out of a population of 325 million) 
(https://institute.progress.im/en/node/2688).  At present there is no disease 
modifying therapy and only moderately efficacious symptomatic treatment.  
Genetic analysis of the autosomal dominant forms of the disease clearly 
implicated APP processing and Aβ deposition as the initiating factor in the 
disease process (1) but therapies based on preventing amyloid deposition have 
so far failed in clinical trials.  While the reason for these failures may be varied 
(2), amyloid deposition begins many years before symptom onset (3) leading to 
a prevalent view that for therapies aimed at preventing amyloid deposition to be 
successful they may need to be given much earlier in the disease process to 
persons who are clinically normal.  A corollary of this is that we need to 
understand other elements of the pathogenic process to identify other targets for 
therapeutic intervention later in the disease process. 
Genetic analysis offers a route both to understanding the pathways involved in 
disease pathogenesis and to identifying people in the general population who are 
at high risk of developing the disease.  In this review, we discuss the pathways 
that have been identified as important in determining the risk of late onset 
disease and also the utility of genetic analysis for predicting those at high risk of 
developing disease. 
Genetic evidence for pathways involved in the pathogenesis 
of Alzheimer’s disease. 
APP processing and Aβ production. 
All the early onset autosomal dominant Alzheimer cases have mutations in either 
the amyloid precursor protein (APP) gene or in presenilin 1 or 2 (PSEN1/2).  The 
presenilins are the major component of the γ-secretase complex.  The work of 
Ihara and colleagues and Chavez Gutierrez/De Strooper and colleagues have 
revealed in great detail how APP and PSEN mutations perturb APP processing 
and Aβ production (5, 6).  All of the pathogenic mutations increase the amounts 
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of longer forms of Aβ which form the central component of plaques: they do this 
by gene dosage effects (Downs syndrome and APP gene duplication cases), 
greater flux through the β-secretase pathway (Swedish mutation), or increasing 
the proportion of longer Aβ (Aβ42 or Aβ43) made during processing.  
Conversely, an APP mutation which reduces the flux through the β-secretase 
pathway reduces the risk of dementia (7).  More recently, mutations that reduce 
the flux through the alternative, α-secretase pathway, have been reported to 
increase the risk of dementia presumably by a compensatory increase in flux 
through the β-secretase pathway (8, 9). 
One of the few candidate genes which have been shown to have a clear 
association with Alzheimer’s disease is SORL1 which is involved in the 
endosome/lysosome trafficking of APP.  Common variability at this locus was 
shown to have an association with Alzheimer’s disease (10) and later, loss of 
function mutations were shown to give rise to almost fully penetrant disease 
(11). 
All these data in autosomal dominant disease are therefore consistent with the 
central importance of Aβ deposition in the initiation of the disease process and 
this has been the major intellectual foundation of the amyloid hypothesis for the 
disease.  This simple hypothesis, as originally conceived was, however, 
postulated in an almost exclusively neuronal way….  APP metabolism in a 
neuron… giving rise to Aβ outside the neuron…. which, somehow, caused a toxic 
reaction inside a neuron…. and then tangle formation and cell death (12).  
Although this has been the dominant disease pathogenesis model for more than 
20 years, in fact, demonstration of relevant toxicity of Aβ has not been 
forthcoming and this, together with an appreciation of the long time frame 
between Aβ deposition and clinical dementia has led to the suggestion that a 
more complex formulation of the hypothesis was called for which was not, 
necessarily, neuronal cell autonomous (13).  Genetic analysis of sporadic late 
onset disease was carried out, in part, to shed new light on whatever other 
pathways may be involved in the disease pathogenesis. 
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The innate immune system and lipid metabolism 
With, first genome wide association studies and later, exome sequencing, genetic 
determinants of late onset “sporadic” disease, beyond the apoe locus started to 
be identified (14, 15).  With the first GWAS it became clear that the major 
pathways being identified were in the innate immune system (16).  With the 
identification of TREM2 through exome sequencing (17, 18) the importance of 
microglia became ever more apparent. 
A conceptual breakthrough came with the realization that, not only were there 
many microglial loci, but also that they formed part of a network of genes 
regulated by the PU.1 myeloid transcription factor and that the gene for this 
transcription factor, SPI1 was also a locus for disease (19).  Thus, many of the 
loci were part of a co-regulated network of microglial genes.  In agreement with 
this finding was the observation, that in APP transgenic mice, many of the 
Alzheimer loci were co-upregulated with TREM2 in response to amyloid 
deposition (20).  This latter analysis showed that genetic variability in microglial 
response to Aβ was one factor in determining ones risk of developing disease. 
These genetic data are consistent with in vivo data using non-radioactive 
labelling to track APP metabolism in both autosomal dominant disease and in 
late onset sporadic disease.  In the former, overproduction of longer Aβ species 
was observed: in the latter, less Aβ clearance was seen (21, 22). 
Integrating the Genetic Findings Concerning Amyloid 
Production and Amyloid Response 
The genetic data summarized above is therefore consistent with the view that 
amyloid deposition is one initiating event in Alzheimer pathogenesis.  However, 
it is notable that many of the microglial genes involved in pathogenesis are lipid 
metabolism genes, apoe, a cholesterol and phospholipid carrier (23), ABCA7 a 
phospholipid transporter  (24) and TREM2 a phospholipid sensing receptor (25) 
as examples.  With this in mind, and considering the initiating event in APP 
processing is intramembranous cleavage, we suggest that the hypothesis that the 
link between the production and aggregation of Aβ and the microglial reaction is 
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the disruption of the neuronal membrane which is sensed and removed, at least 
in part by the activated microglia (26).  We would suggest that it is the slow 
failure of this removal and repair process that underlies the long prodrome of 
Alzheimer’s disease. 
The Time Course of Alzheimer’s Disease 
The evidence that Alzheimer’s disease had a long prodromal phase, essentially 
symptom free has been in the literature for a very long time, especially from the 
work on Down syndrome from Mann and from Wisniewski and her colleagues 
(27, 28).  However, it was with the development of imaging and CSF biomarkers 
that the importance of this long prodrome was more generally recognized (3).  
This realization has partially resolved the longstanding argument about the large 
number of people who die apparently with intact cognition, but with extensive 
amyloid pathology (29).  This long timeframe is difficult to reconcile with a 
simple metabolic amyloid cascade and is more consistent with a complex tissue 
response being important in the determination of events after amyloid 
deposition.  This timeframe also may explain the failure of at least some of the 
anti-amyloid trials since most of these drugs did not remove amyloid, but rather 
prevented further deposition (2).  
Genetic Prediction and Alzheimer’s Disease 
While the reasons for the failure of the anti-amyloid clinical trials is likely to 
have been varied (2, 4), it is likely that one of the important confounds has been 
the poor diagnostic accuracy in those trials carried out without amyloid imaging 
or CSF assessment (34, 35).  Of course, this diagnostic accuracy is worse early in 
the disease and in those individuals who were apoe4 negative (35).  Although 
apoe is the strongest predictor of late onset AD, the genetic heritability explained 
by this locus is not high (h2=4.8% [95% CI: 3.2-6.3%) (30) as compared to 
genome-wide estimates (h2=24-53% )(31-33). The late onset (60+) AD risk 
prediction accuracy by apoe alone varies with age with a better prediction in 
younger group, and is about AUC=68% [95% CI: 66%-69%] with e4 + e2 alleles 
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as predictors  (36).  However this accuracy is not sufficient for clinical 
applications or trials (34). 
Genome-wide association studies allow researchers to summarise genome-wide 
genotype data into a variables that measures genetic liability to a disorder or a 
trait. Two very closely related approaches have been taken called polygenic risk 
score (PRS) analysis and polygenic hazard score analysis (PHS).   We have 
recently formally compared these statistical approaches using the recent GWAS 
data and show that they give essentially identical results under most 
circumstances (37).  PRS is calculated from genome-wide association study 
summary statistics, summing the number of risk alleles carried by an individual, 
weighted by the effect size from the discovery GWAS. Since GWAS captures a 
much higher proportion of genetic variability than apoe alone, the prediction 
accuracy by PRS is higher with an area under the curve (AUC) of between 75% 
and 84% in clinical and pathology confirmed samples, respectively (36, 30). 
These AUC estimates are very close the maximal prediction accuracy (introduced 
by Wray and colleagues (40)) which can be achieved based upon SNP-based 
heritability captured by the whole genome (39). When apoe is included to the 
PRS, the majority of the people at high extreme of the PRS distribution contain e4 
allele(s), however the predictive accuracy of PRS in pathologically confirmed E3 
homozygotes is also to high and equivalent to the predictive accuracy of the 
whole dataset (38). Figure 1 illustrates the clear differences in the distributions 
of PRS for the cases split by apoe genotypes, and controls. 
While the polygenic scores predict general liability of an individual to develop 
AD within lifetime, this approach can be taken further to predict particular 
aspects of the disease such as the age at onset (37, 40). Targeting risk associated 
with disease specific pathways (16, 42) may additionally provide insight for 
predicting the endophenotypes of AD. As two examples Ahmad and colleagues 
(43) have shown that the endocytosis pathway is relevant in the prodromal phase
of AD in subjects with MCI and that immune response and clathrin/AP2 adaptor
complex pathways may be relevant for brain-related early endophenotypes of AD
and we have shown that the risk of amyloid deposition is almost entirely
determined by apoe genotype while the risk of Alzheimer’s disease is has an
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additive dependence on the other risk genes implying that different genetic loci 
have risk conveying effects at different stages of disease aetiology (44). Thus, in 
the design of clinical trials and interventions, one can imagine a using polygenic 
analysis as a rapid and cheap screening tool to select persons for biomarker 
analysis as part of the clinical trial section process.  One could then use this 
analysis as a tool to select individuals for iPSC generation either based on their 
overall score or by their pathway specific score. 
What is left to be done? 
The work summarised above illustrates the considerable progress that has been 
made in dissecting the genetic architecture of Alzheimer’s disease in terms of 
both the pathways involved in the disease and in the prediction of the disease.  In 
these broad areas, there is progress still to be made, but this is likely to be 
incremental.  There are, however, large gaps in our knowledge.  The published 
data is almost entirely based on simple case control analysis of Caucasian 
samples.  There has been little attempt to see whether there are epistatic 
interactions between loci or whether different loci contributed to different 
aspects of the pathology.  Nor has there been much attempt to understand the 
genetics of the rate of decline of disease.  Finally, other syndromes, such as 
Dementia with Lewy Bodies (DLB) and Progressive Supranuclear Palsy (PSP) 
have related pathologies to Alzheimer’s disease but these have not had the 
resources or sample numbers to make as much progress as has occurred in AD.   
Analysis of non-Caucasian Populations 
While it is likely that in other populations the same general pathways to 
pathogenesis will operate, the precise alleles and loci involved in disease will be 
different.  This is certainly true in Parkinson’s disease where the haplotype 
structure differences mean, for example, that the MAPT locus, prominent in 
Caucasians, is not seen in Asian populations (45 q.v. 46).  So far there is limited 
information on Asian populations (47).  These early Asian studies resemble the 
early studies in Caucasians before large consortia were formed to allow large 
sample numbers to be achieved.  Analysis of African American samples has been 
initiated and has already yielded interesting results with, for example, the 
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identification of a reasonably common reduced function variant in ABCA7 that 
contributes to disease risk (48).  This latter finding illustrates how analysis of 
non-Caucasian populations can help in the identification of informative alleles 
for disease modeling.  However, far more analysis of non-Caucasian samples will 
be required before we can apply effective polygenic risk analysis to the 
prediction of disease in these populations. 
Epistasis 
A discussion point in the genetics of complex diseases is whether non-additive 
genetic interaction effects contribute to risk. The standard approach to GWAS 
has assumed an additive model, which, in statistical terms, is equivalent to 
looking for the main effects of variants contributing to disease risk. The 
assumption of additivity has been effective, but it is also pragmatic, since looking 
at the effects of many 100,000s of SNPs would be computationally expensive if 
all combinations of interactions were considered (49). Although computing is 
getting more powerful, extremely large sample sizes will be required to achieve 
sufficient power to detect small genetic interaction effect sizes, as would be 
expected in most complex genetic traits, given the multiple testing constraints. 
The extent to which genetic interactions contribute to risk in AD is unknown. 
The usual practice is to analyse for interaction only the most associated SNPs, 
however some analyses suggested that testing for interactions between SNPs 
with known main effects (e.g. genome-wide significant SNPs) is unlikely to be the 
best strategy, as the majority of interactions involved SNPs that did not have a 
significant main effect on gene expression (50).  
We would anticipate that with the current widely accepted statistical 
methodology (testing for SNPxSNP pairwise interaction with regression 
modelling), interaction analyses are unlikely to provide informative results and 
generate reliable biological hypotheses. Instead these studies could be 
hypothesis driven rather than hypothesis free. The AD field recently produced a 
number of interesting biologically relevant hypotheses concerning interactions 
(e.g. 19) which could be further explored and tested for interactions with 
regression models, accounting for interactions and/or hierarchical models 
allowing multiple levels of random effects.  These studies all require access to the 
 9 
primary genotype data rather than summary statistics and assembling data sets 
of cases and controls in such a format as to allow these analyses is a major 
impediment for these analyses. 
Genetic Analyses of Alzheimer-Related markers, Rates of Progression and 
Atypical Phenotypes 
Nearly all of the analyses so far have been case-control design and these, as 
reviewed above, have been productive.  There have been relatively few attempts 
to assess genetic risk for more complex phenotypes.  Such phenotypes could 
include PET amyloid positivity, rate of disease of progression amongst others.  
None of these studies, so far has been large enough to completely dissociate 
these endophenotypes from disease risk, but there are already indications, if not 
proof, that they are likely to yield different loci from simple case control 
analyses.  The rate of progression in AD has been found to vary widely between 
individuals, with numerous factors thought to drive this heterogeneity.  So far 
GWAS for cognitive decline has only been reported for relatively small samples 
(51-53). These studies rule out a large effect of APOE and this suggests different 
mechanisms underlying disease initiation and progression.  Understanding the 
genetic factors underlying rates of decline is clearly of interest since our primary 
therapeutic goal is to slow the decline in those with disease and thus the 
pathways identified by this approach will be of interest in drug development. 
Most cases of AD have a hippocampal presentation with initial problems in 
creating new memories.  There are two exceptions: some individuals, especially 
with presenilin mutations, have initial symptoms including spastic paraparesis 
(54) and a proportion of AD cases have initial symptoms of visual disturbances
and initiating pathology in the occipital, visual cortex (55).  Genome wide
association studies of this variant of AD, suggests that there may be subtle
differences in the genetic risk loci for this syndrome, but larger numbers are
required for this to be established (56).
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Genetic Analysis of Progressive Supranuclear Palsy (Tangle Disease) and 
Dementia with Lewy Bodies (Plaques and Lewy bodies). 
In AD, the predominant (but not the only) pathologies are amyloid plaques and 
tau tangles.  The relationship between these pathologies has been endlessly 
debated.  The genetic analysis of these related diseases may provide insight into 
genetic risk factors influencing the formation of tangles (56) and the relationship 
between plaques and Lewy bodies as a contrast to the relationship between 
plaques and tangles (57).  Genetic analyses of both these diseases has been 
hampered by the fact that clinical diagnosis is rather poor and relatively few 
samples have been available through brain banks. 
Concluding Remarks 
The findings from genetic analysis have been the driving force for our 
understanding of the pathogenesis of the dementias so far.  With the huge 
increase in the number of loci that genetic analysis has discovered has come a 
deeper understanding of that pathogenesis.  However, so far, this increase in 
knowledge has not led to better treatments.  We have to believe that with a 
deeper understanding of the pathogenic processes will come effective 
treatments and more accurate and earlier diagnoses.  Over the last 5 years, the 
emphasis has started to switch from locus identification, to the integration of 
disparate genetic and phenotypic data.  We can expect that this process will 
continue and our views on how to prevent the disease will move from stopping a 
linear models of disease to ones in which we see our goal as rebalancing a 
dysfunctional network. 
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